Sort
82,697 grants matching “vaccine development”
A single-dose prophylactic Japanese Encephalitis vaccine
$3,104,879Eszter Nagy · Valneva Austria Gmbh · U01 · FY2006 · AI
SPORE in Prostate Cancer
$3,104,009Baylor College Of Medicine · P50 · FY2003 · CA
CENTERS OF EXCELLENCE FOR INFLUENZA RESEARCH AND RESPONSE: UNIVERSAL INFLUENZA VACCINE RESEARCH ACTIVITIES
$3,103,691Andrew Pekosz · Johns Hopkins University · N01 · FY2022 · AI
Strategies for Eliciting bnAbs against Conserved HIV-1 Quaternary Epitopes
$3,103,251Abraham Pinter · Univ Of Med/Dent Of Nj-Nj Medical School · P01 · FY2012 · AI
Integrated Support Services Core
$3,102,344Elke C Muhlberger · Boston University Medical Campus · UC7 · FY2018 · AI
IGERT: Collaborative Research and Education in Agricultural Technologies and Engineering (CREATE)
$3,100,065Karen A McDonald · University Of California-Davis · · FY2007 · EDU
Cleaved, stabilized HIV-1 Env trimers for structural and vaccine studies
$3,100,000John P Moore · Weill Medical Coll Of Cornell Univ · P01 · FY2018 · AI
Cleaved, stabilized HIV-1 Env trimers for structural and vaccine studies
$3,100,000John P Moore · Weill Medical Coll Of Cornell Univ · P01 · FY2015 · AI
Cleaved, stabilized HIV-1 Env trimers for structural and vaccine studies
$3,100,000John P Moore · Weill Medical Coll Of Cornell Univ · P01 · FY2019 · AI
Nanomedicine Center for Nucleoprotein Machines
$3,100,000Gang Bao · Georgia Institute Of Technology · PN2 · FY2011 · EY
Cleaved, stabilized HIV-1 Env trimers for structural and vaccine studies
$3,099,999John P Moore · Weill Medical Coll Of Cornell Univ · P01 · FY2017 · AI
University of Pittsburgh Clinical Trials Unit
$3,099,468John W Mellors · University Of Pittsburgh At Pittsburgh · UM1 · FY2013 · AI
Development of a COVID-19 Vaccine
$3,099,031Raymond Goodrich · Colorado State University · N01 · FY2020 · AI
HIV Prevention Trials Network: Network Laboratory
$3,098,206Susan H Eshleman · Johns Hopkins University · U01 · FY2006 · AI
WNPRC ANIMAL SERVICES DIVISION
$3,098,062Saverio Vincent Capuano · University Of Wisconsin-Madison · P51 · FY2010 · RR
A STUDY TO ASSESS EFFICACY, SAFTETY AND PHARMACOKINETICS OF EYU688 IN HEALTHY PARTICIPANTS CHALLENGED WITH DENGUE SEROTYPE 2
$3,096,871Anna Palmer Durbin · Johns Hopkins University · N01 · FY2023 · AI
Task A44: Ferret Models for the Evaluation of Influenza Vaccines and Vaccine Strategies
$3,096,401Kevin Walters · Southern Research Institute · N01 · FY2020 · AI
Leadership Group for the Infectious Diseases Clinical Research Consortium (IDCRCLG) â Mix & Match DMID #21-0012 {Supplement #7}
$3,094,264David S Stephens · Emory University · UM1 · FY2021 · AI
Randomized Trial of High-Dose Rifampin in Patients with New Smear-Positive TB
$3,094,141Carole D Mitnick · Harvard Medical School · U01 · FY2012 · AI
Cellular Immunity to Category A-C Viruses in Humans
$3,092,533Univ Of Massachusetts Med Sch Worcester · U19 · FY2004 · AI
REAGENT RESOURCE SUPPORT FOR AIDS VACCINE DEVELOPMENT
$3,090,667Ronald Brown · · N01 · FY2007 · AI
CHEMOKINE ADJUVANTS FOR BIOTHREAT PATHOGEN VACCINES
$3,088,117Chemocentryx, Inc. · U19 · FY2004 · AI
Assays to Support Development of Malaria Transmission Blocking Vaccines
$3,087,956Patrick Duffy · National Institute Of Allergy And Infectious Diseases · ZIA · FY2020 · AI
Preventive and therapeutic T cell vaccines to mitigate HIV-1 replication; Preven
$3,087,817Genoveffa Franchini · Basic Sciences · Z01 · FY2007 · CA
Vaccination and infection: indicators of immunological health and responsiveness
$3,087,546Mark M Davis · Stanford University · U19 · FY2012 · AI